January 18, 2023 News by Marisa Wexler, MS FSD Asking to Open Trial of Lucid-MS, Myelin-protecting Therapy FSD Pharma has submitted an application to Health Canada asking to start a Phase 1 clinical trial of Lucid-MS, the company’s experimental and myelin-protective oral therapy for people withĀ multiple sclerosis (MS). The trial will not involve patients and is designed to investigate the safety and tolerability of…
May 13, 2022 News by Lindsey Shapiro, PhD NervGen Cleared to Enroll Final Group in Trial of NVG-291 NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical trial of NVG-291, an investigational treatment for multiple sclerosis (MS) and other nervous system diseases. A safety review committee cleared the…
January 7, 2022 News by Yedida Y Bogachkov PhD Phase 1 Trial of ANK-700 for RRMS Advancing to Multiple Doses A Phase 1 clinical trial investigating the safety and tolerability ofĀ Anokion‘s ANK-700 in people withĀ relapsing-remitting multiple sclerosis (RRMS) has begun enrolling patients for its multiple ascending dose part. This opening of the study’s second part follows positive safety signs in patients given the one of two doses of…
November 5, 2021 News by Steve Bryson, PhD Nerve Repair Therapy NVG-291 Safe, Well-tolerated in Healthy People A single dose of NVG-291, a potential nerve repair therapy for multiple sclerosis (MS), was safe and well-tolerated among healthy volunteers in a Phase 1 safety trial, and was found to have favorable pharmacological properties, new data show. Given the positive results thus far, a safety committee supervising…
August 27, 2019 News by Marisa Wexler, MS Phase 1 Clinical Trial of EHP-101 Concludes with Positive Safety Results The first in-human clinical trial of EHP-101, an investigational treatment for multiple sclerosis (MS) and systemic scleroderma (SSc), has been successfully completed,Ā Emerald Health PharmaceuticalsĀ (EHP) announced. EHP-101 demonstrated it was safe and well-tolerated in healthy volunteers, supporting further clinical development ofĀ EHP-101 in future Phase 2 clinical trials. The…
August 6, 2019 News by Marta Figueiredo, PhD Phase 1 Study Finds T20K, Plant Protein-derived Compound for MS, Safe and Tolerable, Cyxone Says A Phase 1 clinical trial foundĀ T20K, Cyxone’s investigational plant protein-derived treatment forĀ multiple sclerosisĀ (MS), to be safe and well-tolerated in healthy men, and raising the possibility that it might work at low doses, the company announced. A next step is to develop an oral formulation for the…
July 17, 2019 News by Joana Carvalho, PhD Phase 1 Trial of T20K, Plant Protein-derived Therapy for MS, Doses 1st Group of Healthy Men A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis (MS), has been dosed in a study taking place in The Netherlands, the company announced. T20K is an investigational…